MiR-888 is an expressed prostatic secretionsderived microRNA that promotes prostate cell growth and migration

Cell Cycle

Volumn 13, Issue 2, 2014, Pages 227-239

  Lewis, Holly ^a   Lance, Raymond ^a   Troyer, Dean ^a   Beydoun, Hind ^a   Hadley, Melissa ^a   Orians, Joseph ^a   Benzine, Tiffany ^a   Madric, Kenya ^a   Semmes, O John ^a   Drake, Richard ^a,b   Esquela Kerscher, Aurora ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

EPS urine; Expressed prostatic secretions urine; MicroRNA; MiR 888; MiRNA; Non coding RNA; Prostate; Prostate cancer

Indexed keywords

MICRORNA; MIR 888; PROTEIN P107; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN888 MICRORNA, HUMAN; SMAD4 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CELL GROWTH; CELL MIGRATION; CELL STRAIN LNCAP; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MALE; PROSTATE CANCER; PROSTATE FLUID; PROSTATE SECRETION; SEMINAL VESICLE; TREATMENT OUTCOME; TUMOR INVASION; CANCER GRADING; CELL MOTION; CELL PROLIFERATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SECRETION (PROCESS); TUMOR CELL LINE; URINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MALE; MICRORNAS; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS; RETINOBLASTOMA-LIKE PROTEIN P107; SMAD4 PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84892579226     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26984     Document Type: Article

References (73)

1. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8:268-78; PMID:18337732; http://dx.doi.org/10.1038/nrc2351 (Pubitemid 351430866)
2. Schröder FH. Review of diagnostic markers for prostate cancer. Recent Results Cancer Res 2009; 181: 173-82; PMID:19213567; http://dx.doi.org/ 10.1007/978-3-540-69297-3-16
3. Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 192-9; PMID:18678846; http://dx.doi.org/10.7326/0003-4819- 149-3-200808050-00009
4. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-34; PMID:22801674; http://dx.doi.org/10.7326/0003-4819-157- 2-201207170-00459
5. Maugeri-Saccà M, Coppola V, Bonci D, De Maria R. MicroRNAs and prostate cancer: from preclinical research to translational oncology. Cancer J 2012; 18: 253-61; PMID:22647362; http://dx.doi.org/10.1097/PPO.0b013e318258b5b6
6. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36:D154-8; PMID:17991681; http://dx.doi.org/10.1093/nar/gkm952 (Pubitemid 351149713)
7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997 (Pubitemid 44629897)
8. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69; PMID:16557279; http://dx.doi.org/10.1038/nrc1840
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045- 5
10. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-14; PMID:18197166; http://dx.doi.org/10.1038/nrg2290
11. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27:1788-93; PMID:17891175; http://dx.doi.org/10.1038/sj.onc.1210809 (Pubitemid 351380263)
12. Gandellini P, Folini M, Zaffaroni N. Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med 2009; 15:381-90; PMID:19716766; http://dx.doi.org/10.1016/j.molmed.2009.07.004
13. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-8; PMID:18663219; http://dx.doi.org/10.1073/pnas.0804549105
14. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-41; PMID:20847327; http://dx.doi.org/10.1373/clinchem.2010.147405
15. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-5; PMID:18318758; http://dx.doi.org/10. 1111/j.1365-2141.2008.07077.x (Pubitemid 351667616)
16. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009; 15: 5473-7; PMID:19706812; http://dx.doi.org/10.1158/1078-0432.CCR-09-0736
17. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012; 106:768-74; PMID:22240788; http://dx.doi.org/10.1038/bjc.2011.595
18. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-9; PMID:20234369; http://dx.doi.org/10.1038/sj.bjc.6605608
19. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 2012; 287: 1527-37; PMID:22128178; http://dx.doi.org/10.1074/ jbc.M111.278705
20. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One 2012; 7:e32832; PMID:22479342; http://dx.doi.org/10.1371/journal.pone.0032832
21. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14:1271-7; PMID:18931683; http://dx.doi.org/10.1038/nm.1880
22. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, Sarkar FH. miR-200 regulates PDGF-Dmediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009; 27: 1712-21; PMID:19544444; http://dx.doi.org/10.1002/stem.101
23. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, Stampfer MR, Futscher BW. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 2010; 5:e8697; PMID:20084174; http://dx.doi.org/10.1371/journal.pone.0008697
24. Vallejo DM, Caparros E, Dominguez M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J 2011; 30: 756-69; PMID:21224847; http://dx.doi.org/10.1038/emboj.2010.358
25. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, Jensen RV, Moskaluk CA, Dutta A. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011; 71: 1313-24; PMID:21212412; http://dx.doi.org/10.1158/0008-5472.CAN-10- 1031
26. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-9; PMID:19008416; http://dx.doi.org/10.1126/science.1165395
27. Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 2010; 9:108; PMID:20478051; http://dx.doi.org/10.1186/1476-4598-9-108
28. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009; 28: 1714-24; PMID:19252524; http://dx.doi.org/10.1038/onc.2009. 19
29. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer 2010; 17:F1-17; PMID:19779034; http://dx.doi.org/10.1677/ERC-09- 0172
30. Gordanpour A, Nam RK, Sugar L, Seth A. MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics. Prostate Cancer Prostatic Dis 2012; 15: 314-9; PMID:22333688; http://dx.doi.org/10.1038/pcan.2012.3
31. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTENtargeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010; 3:ra29; PMID:20388916; http://dx.doi.org/10.1126/scisignal.2000594
32. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-5; PMID:21240262; http://dx.doi.org/10.1038/nm.2284
33. Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, Zaman MS, Deng G, Tanaka Y, Dahiya R. miRNA-708 control of CD44(+) prostate cancer- initiating cells. Cancer Res 2012; 72: 3618-30; PMID:22552290; http://dx.doi.org/10.1158/0008-5472.CAN-12-0540
34. Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 2012; 11: 1166-73; PMID:22402125; http://dx.doi.org/10.1158/1535-7163.MCT-12-0100
35. Wang M, Stearns ME. Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. Differentiation 1991; 48: 115-25; PMID:1773917; http://dx.doi.org/10.1111/j.1432-0436.1991.tb00250.x
36. Murata T, Takayama K, Katayama S, Urano T, Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y, et al. miR-148a is an androgenresponsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 2010; 13:356-61; PMID:20820187; http://dx.doi.org/10.1038/pcan.2010.32
37. Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL. Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet 2012; 21:3112-27; PMID:22505583; http://dx.doi.org/10.1093/hmg/dds139
38. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282: 23716-24; PMID:17569667; http://dx.doi.org/10.1074/jbc. M701805200 (Pubitemid 47311902)
39. Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, Goan YG, Lu PJ. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 2009; 28: 3360-70; PMID:19597470; http://dx.doi.org/10.1038/onc.2009.192
40. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-14; PMID:17604727; http://dx.doi.org/10.1016/j.cell.2007.04.040 (Pubitemid 46970709)
41. Li J, Liu Y, Dong D, Zhang Z. Evolution of an X-linked primate-specific micro RNA cluster. Mol Biol Evol 2010; 27: 671-83; PMID:19933172; http://dx.doi.org/10.1093/molbev/msp284
42. Belleannée C, Calvo E, Thimon V, Cyr DG, Légaré C, Garneau L, Sullivan R. Role of microRNAs in controlling gene expression in different segments of the human epididymis. PLoS One 2012; 7:e34996; PMID:22511979; http://dx.doi.org/10.1371/journal.pone.0034996
43. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997; 18:1215-23; PMID:9214605; http://dx.doi.org/10.1093/carcin/18.6.1215 (Pubitemid 28132513)
44. Troyer DA, Tang Y, Bedolla R, Adhvaryu SG, Thompson IM, Abboud-Werner S, Sun LZ, Friedrichs WE, deGraffenried LA. Characterization of PacMetUT1, a recently isolated human prostate cancer cell line. Prostate 2008; 68: 883-92; PMID:18361412; http://dx.doi.org/10.1002/pros.20758 (Pubitemid 351845219)
45. Villers AA, McNeal JE, Redwine EA, Freiha FS, Stamey TA. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol 1990; 143: 1183-7; PMID:2342179 (Pubitemid 20193069)
46. Epstein JI, Carmichael M, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 1993; 149: 1040-5; PMID:8483205 (Pubitemid 23133766)
47. Pierorazio PM, Ross AE, Schaeffer EM, Epstein JI, Han M, Walsh PC, Partin AW. A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. J Urol 2011; 185:1691-7; PMID:21419448; http://dx.doi.org/10.1016/j.juro.2010.12.059
48. Sapre N, Pedersen J, Hong MK, Harewood L, Peters J, Costello AJ, Hovens CM, Corcoran NM. Re-evaluating the biological significance of seminal vesicle invasion (SVI) in locally advanced prostate cancer. BJU Int 2012; 110(Suppl 4): 58-63; PMID:23194127; http://dx.doi.org/10.1111/j.1464-410X.2012.11477.x
49. Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, et al. In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res 2010; 9: 2109-16; PMID:20334419; http://dx.doi.org/10.1021/pr1001498
50. Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics 2009; 72:907-17; PMID:19457353; http://dx.doi.org/10.1016/j.jprot. 2009.01.007
51. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-22; PMID:17699775; http://dx.doi.org/10.1158/0008-5472.CAN-07-1083 (Pubitemid 47281364)
52. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: MicroRNAs in Cancer. Cell 2009; 137:586-e1, e1; PMID:19410551; http://dx.doi.org/10.1016/j.cell. 2009.04.040
53. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008; 7: 759-64; PMID:18344688; http://dx.doi.org/10.4161/cc.7.6.5834 (Pubitemid 351520040)
54. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-5; PMID:17616669; http://dx.doi.org/10.1158/0008-5472.CAN-07-0533 (Pubitemid 47037493)
55. Chen C, Bhalala HV, Vessella RL, Dong JT. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 2003; 55:81-8; PMID:12661032; http://dx.doi.org/10.1002/pros.10205 (Pubitemid 36443994)
56. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, et al.; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-21; PMID:18264097; http://dx.doi.org/10.1038/ng.90 (Pubitemid 351311772)
57. Ghosh AK, Steele R, Ray RB. c-myc Promoterbinding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway. J Biol Chem 2005; 280: 14325-30; PMID:15805119; http://dx.doi.org/10.1074/jbc.M413313200 (Pubitemid 40517336)
58. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, Asmann YW, Klee GG, Ballman KV, Jenkins RB. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 2008; 3:e2318; PMID:18846227; http://dx.doi.org/10. 1371/journal.pone.0002318
59. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 2010; 10:599; PMID:21044312; http://dx.doi.org/10.1186/1471-2407-10-599
60. Bera TK, Maitra R, Iavarone C, Salvatore G, Kumar V, Vincent JJ, Sathyanarayana BK, Duray P, Lee BK, Pastan I. PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. Proc Natl Acad Sci U S A 2002; 99: 3058-63; PMID:11880645; http://dx.doi.org/10.1073/pnas.052713699 (Pubitemid 34240585)
61. Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul JW, Srivastava S. A novel androgen- regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 2000; 66: 257-63; PMID:10873380; http://dx.doi.org/10.1006/geno.2000.6214 (Pubitemid 30481772)
62. Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N, Harlow E. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 1993; 7(7A):1111-25; PMID:8319904; http://dx.doi.org/10.1101/gad.7.7a.1111 (Pubitemid 23207404)
63. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B, Giordano A. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994; 54: 5556-60; PMID:7923196 (Pubitemid 24346246)
64. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, et al. SMAD4- dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470:269-73; PMID:21289624; http://dx.doi.org/10.1038/nature09677
65. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 2011; 71:1668-79; PMID:21432867; http://dx.doi.org/10.1002/pros.21383
66. Li Y, Wang HY, Wan FC, Liu FJ, Liu J, Zhang N, Jin SH, Li JY. Deep sequencing analysis of small non-coding RNAs reveals the diversity of microRNAs and piRNAs in the human epididymis. Gene 2012; 497: 330-5; PMID:22313525; http://dx.doi.org/10.1016/j.gene.2012.01.038
67. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, Evans A, Yousef GM. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 2011; 59:721-30; PMID:21272993; http://dx.doi.org/10.1016/j.eururo.2011.01.004
68. Ryland GL, Bearfoot JL, Doyle MA, Boyle SE, Choong DY, Rowley SM, Tothill RW, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group. MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS One 2012; 7:e35805; PMID:22536442; http://dx.doi.org/10.1371/journal.pone.0035805
69. Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S, Leslie KK. microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep 2011; 26: 995-1002; PMID:21725615
70. Wang J, Xiang G, Mitchelson K, Zhou Y. Microarray profiling of monocytic differentiation reveals miRNA-mRNA intrinsic correlation. J Cell Biochem 2011; 112: 2443-53; PMID:21538479; http://dx.doi.org/10.1002/jcb.23165
71. Claudio PP, Zamparelli A, Garcia FU, Claudio L, Ammirati G, Farina A, Bovicelli A, Russo G, Giordano GG, McGinnis DE, et al. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 2002; 8: 1808-15; PMID:12060621 (Pubitemid 34633739)
72. Yang G, Yang X. Smad4-mediated TGF-beta signaling in tumorigenesis. Int J Biol Sci 2010; 6: 1-8; PMID:20087440; http://dx.doi.org/10.7150/ijbs.6.1
73. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova- Agadjanyan EL, Stirewalt DL, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108: 5003-8; PMID:21383194; http://dx.doi.org/10.1073/pnas.1019055108